Claspin overexpression is associated with high‐grade histology and poor prognosis in renal cell carcinoma

Abstract

Renal cell carcinoma (RCC) is one of the most common human cancers. We previously reported that claspin is a key regulator in the progression of gastric cancer, and it likely plays an important role in cancer stem cells of gastric cancer. However, the significance of claspin in RCC has not been examined. First, we analyzed the expression and distribution of claspin in 95 RCC cases by immunohistochemistry. In the nonneoplastic kidney, the staining of claspin was either weak or absent, whereas RCC tissue showed nuclear staining. In total, claspin expression was detected in 45 (47%) of 95 RCC cases. The claspin staining appeared relatively stronger in high nuclear grade RCC than in low nuclear grade RCC. Claspin‐positive RCC cases were associated with higher T grade, tumor stage, nuclear grade, vein invasion, and poorer prognosis. CLSPN siRNA treatment decreased RCC cell proliferation. The levels of phosphorylated Erk and Akt were lower in CLSPN siRNA‐transfected RCC cells than in control cells. In addition, claspin was coexpressed with CD44, epidermal growth factor receptor, p53, and programmed death ligand‐1. These results suggest that claspin plays an important role in tumor progression in RCC and might be a prognostic marker and novel therapeutic target molecule.

Specific expression of survivin, SOX9, and CD44 in renal tubules in adaptive and maladaptive repair processes after acute kidney injury in rats

“…Several reports have shown that CD44 is expressed in various types of tumors and in the livers in patients with nonalcoholic steatohepatitis (NASH). Moreover, soluble CD44 levels are increased in the serum of patients with colorectal cancer and NASH (Gurzu, Kobori, Fodor, & Jung, 2019;Kobayashi et al, 2020;Masson et al, 1999;Patouraux et al, 2017). Because CD44 was expressed in renal tubules immediately after I/R injury without fibrotic lesions in the current study, detection of CD44 in liquid biopsies using urine or serum samples after kidney injury may have applications in predicting the AKI to CKD transition.…”

Claspin Overexpression Promotes Tumor Progression and Predicts Poor Clinical Outcome in Prostate Cancer

“…In some up-to-date articles, it has been reported to increase resistance to various therapies in lung and ovarian cancers (Choi et al, 2012;Ito et al, 2018). In addition, CLSPN coexpresses with PDL-1, CD44, EGFR, p53 and acts as a poor prognosis fact in renal cell carcinoma (Kobayashi et al, 2020). Besides, some researches showed that overexpressed CLSPN leads to solid tumors poor prognosis and progression (Allera-Moreau et al, 2012;Wang et al, 2017;Kobayashi et al, 2019).…”

“…The decrease of CLSPN may induce genomic instability and cause cancer progress. More importantly, high CLSPN expression is linked to the poor prognosis and cancer promoted effect in bladder cancer, renal cell carcinoma, breast cancer, and lung cancer (Sato et al, 2012;Li et al, 2013;Choi et al, 2014;Kobayashi et al, 2020). However, the role of CLSPN in PCa is still to be elucidated.…”

Identification of Prognostic Biomarkers and Correlation with Immune Infiltrates in Hepatocellular Carcinoma Based on a Competing Endogenous RNA Network

“…They also found that patients with higher T grade, advanced tumor stage, vein invasion and inferior prognosis were likely to exhibit stronger CLSPN staining. In addition, CLSPN activates the AKT signaling pathway and is co-expressed with several known tumorrelated genes, such as programmed death ligand-1, epidermal growth factor receptor et al [47]. Previous studies have reported that KIF23 is a kinesin-like motor protein that plays a significant role in cytokinesis and has two splice variants, KIF V1 and KIFV2, which are overexpressed in HCC samples but were not detected in nontumor tissues.…”